Philadelphia Inquirer Profiles CEO of Biosyn, Company's Efforts to Develop Microbicide to Prevent STDs, Including HIV
January 3, 2005
The Philadelphia Inquirer on Monday profiled Anne-Marie Corner, president and CEO of Huntington, Pa.-based biotechnology firm Biosyn, which is working to develop a vaginal microbicide to prevent sexually transmitted diseases, including HIV/AIDS. Corner is overseeing the final development of Savvy, a microbicide that is expected to be on the market in 2007 (McCullough, Philadelphia Inquirer, 1/3). Microbicides include a range of products -- such as gels, films, sponges and other products -- that could help prevent the sexual transmission of HIV and other STDs (Kaiser Daily HIV/AIDS Report, 11/9/04). In the fall of 2004, Corner sold the rights to Savvy to Cellegy Pharmaceuticals, a Calif.-based biotechnology company. The microbicide is currently undergoing final human testing in Ghana, Nigeria and the United States (Philadelphia Inquirer, 1/3). The complete article, which profiles nine other leaders in health and biotechnology in the Philadelphia area, is available online.
This article was provided by Henry J. Kaiser Family Foundation. It is a part of the publication Kaiser Daily HIV/AIDS Report. Visit the Kaiser Family Foundation's website to find out more about their activities, publications and services.